Analysts expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to report $5.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Paratek Pharmaceuticals’ earnings. Paratek Pharmaceuticals posted sales of $30,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 16,566.7%. The business is scheduled to report its next quarterly earnings results on Thursday, March 1st.
On average, analysts expect that Paratek Pharmaceuticals will report full year sales of $5.00 million for the current year, with estimates ranging from $7.50 million to $15.00 million. For the next year, analysts anticipate that the company will post sales of $8.47 million per share, with estimates ranging from $50,000.00 to $22.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.93) by $0.16. The company had revenue of $0.01 million during the quarter. Paratek Pharmaceuticals had a negative return on equity of 100.84% and a negative net margin of 1,236.38%.
Shares of Paratek Pharmaceuticals (PRTK) opened at $12.65 on Friday. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49. Paratek Pharmaceuticals has a 52-week low of $11.85 and a 52-week high of $29.00. The company has a market capitalization of $353.45, a PE ratio of -3.39 and a beta of 0.27.
In other news, Director Robert S. Radie sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $14.22, for a total transaction of $42,660.00. Following the sale, the director now owns 9,330 shares of the company’s stock, valued at approximately $132,672.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Adam Woodrow sold 14,333 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $13.87, for a total value of $198,798.71. Following the sale, the vice president now directly owns 62,367 shares in the company, valued at approximately $865,030.29. The disclosure for this sale can be found here. Insiders have sold a total of 40,664 shares of company stock worth $573,226 in the last three months. Corporate insiders own 4.90% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Omni Partners LLP purchased a new stake in Paratek Pharmaceuticals in the 3rd quarter valued at approximately $3,707,000. Alyeska Investment Group L.P. raised its holdings in Paratek Pharmaceuticals by 473.4% in the 3rd quarter. Alyeska Investment Group L.P. now owns 916,349 shares of the specialty pharmaceutical company’s stock valued at $23,000,000 after acquiring an additional 756,535 shares during the last quarter. C WorldWide Group Holding A S raised its holdings in Paratek Pharmaceuticals by 46.8% in the 3rd quarter. C WorldWide Group Holding A S now owns 645,100 shares of the specialty pharmaceutical company’s stock valued at $16,192,000 after acquiring an additional 205,700 shares during the last quarter. Davidson Kempner Capital Management LP acquired a new position in Paratek Pharmaceuticals in the 3rd quarter valued at $6,727,000. Finally, State Street Corp raised its holdings in Paratek Pharmaceuticals by 112.3% in the 2nd quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock valued at $14,850,000 after acquiring an additional 325,856 shares during the last quarter. 75.05% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “$5.00 Million in Sales Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/10/5-00-million-in-sales-expected-for-paratek-pharmaceuticals-inc-prtk-this-quarter.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.